Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Abstract: Disclosed is a fuming furnace with a lead collecting and discharging function, the fuming furnace comprising a furnace body; the furnace body is provided with a hearth therein and a tuyere thereon; the bottom of the hearth forms a molten pool; the furnace body is further provided with a slag discharging outlet and a lead discharging outlet thereon; the furnace body comprises a furnace bottom water jacket and a hearth water jacket; the furnace bottom water jacket is provided with a refractory brick layer at the inner wall thereof; the refractory brick layer is provided with a lead collecting and discharging channel therein for collecting and discharging lead; the lead collecting and discharging channel is in communication with the lead discharging outlet, and the lead collecting and discharging channel is in communication with the molten pool via joints between the refractory bricks forming the refractory brick layer.

Abstract: The present disclosure discloses a refractory protection layer for a metallurgical furnace, which includes a insulating layer, a permanent layer built with a refractory brick and arranged on the insulating layer, a working layer built with a refractory brick and arranged on the permanent layer, and a first anti-permeation layer made of ramming mass and arranged on the working layer. The refractory protection layer for the metallurgical furnace described in the present disclosure embodiments has both high temperature resistance and good permeability resistance.

Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Abstract: The present disclosure discloses a refractory protection layer for a metallurgical furnace, which includes a insulating layer, a permanent layer built with a refractory brick and arranged on the insulating layer, a working layer built with a refractory brick and arranged on the permanent layer, and a first anti-permeation layer made of ramming mass and arranged on the working layer. The refractory protection layer for the metallurgical furnace described in the present disclosure embodiments has both high temperature resistance and good permeability resistance.

Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Abstract: Disclosed is a fuming furnace with a lead collecting and discharging function, the fuming furnace comprising a furnace body; the furnace body is provided with a hearth therein and a tuyere thereon; the bottom of the hearth forms a molten pool; the furnace body is further provided with a slag discharging outlet and a lead discharging outlet thereon; the furnace body comprises a furnace bottom water jacket and a hearth water jacket; the furnace bottom water jacket is provided with a refractory brick layer at the inner wall thereof; the refractory brick layer is provided with a lead collecting and discharging channel therein for collecting and discharging lead; the lead collecting and discharging channel is in communication with the lead discharging outlet, and the lead collecting and discharging channel is in communication with the molten pool via joints between the refractory bricks forming the refractory brick layer.

Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Abstract: A method of determining whether a subject has cancer or has a risk of getting cancer comprises: detecting the concentration of Hsp90a in a blood sample of the subject; and if the concentration reaches or exceeds a preset threshold value, determining that the subject has cancer or has a risk of getting cancer, where the threshold value is selected from a range from 50 ng/ml to 120 ng/ml; for example, the threshold value may be 50, 53, 56, 62, 63, 64, 67, 72, 82, 85 or 117 ng/ml, and a numerical value within the ±15% range of the threshold value is regarded having equivalent significance for determination.

Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Abstract: A system and method for preventing protein aggregation is developed by covalent modification of proteins with organic molecules that can preserve the native protein folding. Proteins are covalently modified with sugar alcohols or cyclodextrins (organic Kosmotropes) or other small molecule drugs by water-driven bioorganic reactions in water. In the water-driven bioorganic reactions, the reagent is stable in water and can modify lysine residues or cysteine residue of a protein at physiological conditions with high yield and fast rate. Proteins and antibodies will be modified by non-natural sugar alcohols. As a result, the efficacy of protein drugs (reduction in aggregation and enzymatic degradation, and increase in blood stream life time) may be improved.

Abstract: A system and method for preventing protein aggregation is developed by covalent modification of proteins with organic molecules that can preserve the native protein folding. Proteins are covalently modified with sugar alcohols or cyclodextrins (organic Kosmotropes) or other small molecule drugs by water-driven bioorganic reactions in water. In the water-driven bioorganic reactions, the reagent is stable in water and can modify lysine residues or cysteine residue of a protein at physiological conditions with high yield and fast rate. Proteins and antibodies will be modified by non-natural sugar alcohols. As a result, the efficacy of protein drugs (reduction in aggregation and enzymatic degradation, and increase in blood stream life time) may be improved.